ArticleBritish journal of clinical pharmacology2019
Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases.
Article in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical characteristics and treatment outcomes of linear IgA bullous dermatosis.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Pooled it
- Vancomycin-induced linear IgA bullous dermatosis mimicking Stevens-Johnson syndrome/toxic epidermal necrolysis treated with etanercept.JAAD case reports · 2026Article
- The cutaneous mirror: leveraging drug-induced skin phenotypes as early visual risk signals for systemic toxicity, a comprehensive review.Frontiers in drug safety and regulation · 2026Review
- Linear IgA Bullous Dermatosis in an Elderly Patient Following Meloxicam and Candesartan Use: A Case Report.Cureus · 2025Article
- Successful treatment of amoxicillin-induced linear IgA bullous dermatosis of childhood with rituximab: A case report and review of the literature.JAAD case reports · 2025Article
- Article
- Immune checkpoint inhibitor-associated linear IgA bullous dermatosis with recalcitrant ocular involvement: a rare presentation.Skin health and disease · 2025Article
- Amoxicillin-induced linear IgA bullous dermatosis mimicking erythema multiforme: a case report.Skin health and disease · 2025Article
- Two case reports of rare cocaine-associated dermatoses: Pyoderma gangrenosum and linear IgA bullous dermatosis.SAGE open medical case reports · 2025Article
- Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments.American journal of clinical dermatology · 2024Review
- Toxic epidermal necrolysis-like linear IgA bullous dermatosis as a manifestation of multiple drug hypersensitivity in the setting of drug reaction with eosinophilia and systemic symptoms.JAAD case reports · 2024Article
- Linear IgA Bullous Dermatosis in Korea Using the Nationwide Health Insurance Database.Journal of clinical medicine · 2024Article
- Linear IgA bullous dermatosis-a fifty year experience of Warsaw Center of bullous diseases.Frontiers in immunology · 2024Review
- Linear IgA dermatosis secondary to treatment with piperacillin-tazobactam in a nonagenarian patient.Postepy dermatologii i alergologii · 2023Article
- Article
- Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine.Journal of cutaneous pathology · 2023Article
- Article
- Road Less Traveled: Drug Hypersensitivity to Fluoroquinolones, Vancomycin, Tetracyclines, and Macrolides.Clinical reviews in allergy & immunology · 2022Review
- Linear Immunoglobulin a Bullous Dermatosis in Children.Frontiers in pediatrics · 2022Review
- Glycopeptide Hypersensitivity and Adverse Reactions.Pharmacy (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsLinear immunoglobin A (IgA) bullous dermatosis is a rare autoimmune dermatosis considered spontaneous or drug-induced (DILAD). We assessed all DILAD cases, determined the imputability score of drugs and highlighted suspected drugs.
methodsData for patients with DILAD were collected retrospectively from the French Pharmacovigilance network (from 1985 to 2017) and from physicians involved in the Bullous Diseases French Study Group and the French Investigators for Skin Adverse Reactions to Drugs. Drug causality was systematically determined by the French imputability method.
resultsOf the 69 patients, 42% had mucous membrane involvement, 20% lesions mimicking toxic epidermal necrolysis (TEN), 21% eosinophil infiltrates and 10% keratinocytes necrosis. Direct immunofluorescence, in 80%, showed isolated linear IgA deposits. Vancomycin (VCM) was suspected in 39 cases (57%), 11 had TEN-like lesions, as compared with three without VCM suspected. Among the 33 patients with a single suspected drug, 85% had an intrinsic imputability score of I4. Among them, enoxaparin, minocycline and vibramycin were previously unpublished. For all patients, the suspect drug was withdrawn; 15 did not receive any treatment. First-line therapy for 31 patients was topical steroids. Among the 60 patients with available follow-up, 52 achieved remission, 10 without treatment. Four patients experienced relapse, four died and five had positive accidental rechallenges.
conclusionsThere is no major clinical difference between DILAD and idiopathic linear IgA bullous dermatosis, but the former features a higher prevalence of patients mimicking TEN. VCM, suspected in more than half of the cases, might be responsible for more severe clinical presentations. We report three new putative drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.